SOURCE: Skystar Bio-Pharmaceutical Co., Ltd

May 12, 2006 11:07 ET

Skystar Bio-Pharmaceutical Co., Ltd Announces Partnership With Tianlong Technology

The Partnership Introduces an Advanced Examination System for Detecting the Avian Bird Flu Virus

XI'AN, CHINA -- (MARKET WIRE) -- May 12, 2006 -- Skystar Bio-Pharmaceutical (OTC BB: SKBI), a leading Bio-Pharmaceutical Company in China, announced a joint venture with Xi'an Tianlong Science and Technology Limited, who has developed a quick and accurate method for detecting the presence of the Avian Flu Virus.

Protecting animals and humans from the Avian Bird Flu Virus has become a major concern in China and all over the world. Early detection and quick examination and is extremely crucial in controlling an outbreak and preventing a pandemic. The appropriate measures can be taken to prevent an outbreak or pandemic if the virus is detected in the early stages.

The Chinese government stipulates that laboratories must use a PCR examination to carry out laboratory nucleic acid examination diagnosis for the avian bird flu. As a result, Skystar Bio-Pharmaceutical Co., Ltd has successfully partnered with Xi'an Tianlong Science and Technology Limited Company for the development of a real-time fluorescence RT-PCR examination system.

Xi'an Tianlong Science and Technology Limited Company is a state-level high technology enterprise specializing in vitro diagnosis medical instruments as well as bio-technology instruments. Xi'an Tianlong has independently developed the TL98A, a Real-Time PCR Gene Expanding Fluorescence Instrument. The TL98A has successfully passed the National Food and Drug Surveillance Administrative Bureau (SFDA) testing. The TL98A has also received a registration permit for use in detecting and diagnosing the Avian Bird Flu Virus. The TL98A has been approved for use in China for all levels of research, including quick diagnosis, clinical research and scientific research for the Avian Bird Flu Virus. According to many expert estimations, the TL98A will become the detection and diagnostic standard for the Avian Bird Flu Virus in China. The TL98A will replace more expensive imports.

This successful partnership with Xi'an Tianlong Science and Technology will be a new source of growth for Skystar both now and in the future. Skystar's continued development of new products, future partnerships and future acquisitions will help solidify Skystar as a leader of the Bio-Pharmaceutical industry in China.

About Skystar Bio-Pharmaceutical

Skystar Bio-Pharmaceutical Company, Ltd. (OTC BB: SKBI). Established in 1997, Skystar is a Bio-Pharmaceutical company that produces and distributes vaccines, microorganisms and 100% organic herbal additives to cure and prevent disease in poultry, livestock, birds and pets. The company's product line consists of more than 60 state-of-the-art products and has over 50 more in the developmental stage. One of the prominent products in the development stage is a feed additive and vaccine for Avian Influenza. Skystar has formed strategic sales distribution networks in 27 provinces and regions throughout China. The State Ministry of Agriculture in China has authorized the additional construction of a new Bio-Pharmaceutical facility, which will also conform to Good Manufacturing Practices (GMP) standards. For more information about Skystar Bio-Pharmaceutical Company, Ltd.'s innovative products and growth plan, please visit www.xa-tx.com or contact Scott Cramer at scramer@skystarbio-pharmaceutical.com (407) 645-4433.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Skystar's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Contact Information